Search Advanced

AIMS Neuroscience

2023, Volume 10, Issue 1: 5-32. doi: 10.3934/Neuroscience.2023002
Previous Article Next Article
Review

Brain-derived neurotrophic factor (BDNF) in schizophrenia research: a quantitative review and future directions

  • 1.
    School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia
  • 2.
    Faculty of Medicine, Medical Campus, Universiti Sultan Zainal Abidin, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Terengganu, Malaysia
  • 3.
    Department of Health Information Management, Universitas Indonesia Maju, Jakarta 12610, Indonesia
  • Received: 20 December 2022 Revised: 13 March 2023 Accepted: 15 March 2023 Published: 17 March 2023

  • This review aims to perform a bibliometric analysis of the research related to brain-derived neurotrophic factor (BDNF) in schizophrenia and offer suggestions for further work. Based on the keywords used, our study retrieved 335 documents for further analysis using a combination of three bibliometric techniques: co-word analysis, document co-citation analysis, and bibliographic coupling. A general rising trend in the number of publications was found in BDNF and schizophrenia research. Researchers from China and the United States have mostly researched BDNF and schizophrenia. Molecular Psychiatry is the most prestigious journal in the field of BDNF and schizophrenia research. The main topics and important research areas are cognition and the involvement of BDNF as a neurobiological marker (pathogenesis, therapy monitoring, and risk factors). Future research is anticipated to concentrate on relevant subjects, such as factors that affect BDNF levels or are connected to BDNF dysfunction in schizophrenia, as well as animal models of schizophrenia, in addition to cognition in schizophrenia.

    Citation: Rozaziana Ahmad, Khairunnuur Fairuz Azman, Rosliza Yahaya, Nazlahshaniza Shafin, Norsuhana Omar, Asma Hayati Ahmad, Rahimah Zakaria, Adi Wijaya, Zahiruddin Othman. Brain-derived neurotrophic factor (BDNF) in schizophrenia research: a quantitative review and future directions[J]. AIMS Neuroscience, 2023, 10(1): 5-32. doi: 10.3934/Neuroscience.2023002

    Related Papers:

  • This review aims to perform a bibliometric analysis of the research related to brain-derived neurotrophic factor (BDNF) in schizophrenia and offer suggestions for further work. Based on the keywords used, our study retrieved 335 documents for further analysis using a combination of three bibliometric techniques: co-word analysis, document co-citation analysis, and bibliographic coupling. A general rising trend in the number of publications was found in BDNF and schizophrenia research. Researchers from China and the United States have mostly researched BDNF and schizophrenia. Molecular Psychiatry is the most prestigious journal in the field of BDNF and schizophrenia research. The main topics and important research areas are cognition and the involvement of BDNF as a neurobiological marker (pathogenesis, therapy monitoring, and risk factors). Future research is anticipated to concentrate on relevant subjects, such as factors that affect BDNF levels or are connected to BDNF dysfunction in schizophrenia, as well as animal models of schizophrenia, in addition to cognition in schizophrenia.


    加载中


    Conflict of interest


    The authors declare no conflict of interest.

    Author contributions


    Conceptualization, Z.O.; data curation, R.A. and N.O.; formal analysis, R.Z. and A.W.; writing—original draft, Z.O. and N.S.; writing—review & editing, K.F.A., R.Y. and A.H.A. All authors have read and agreed to the published version of the manuscript.

    [1] Institute of health Metrics and Evaluation (IHME)Global Health Data Exchange (GHDx). Available from: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7
    [2] Sullivan PF, Daly MJ, O'Donovan M (2012) Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Gene 13: 537-551. https://doi.org/10.1038/nrg3240
    [3] Xiu MH, Li Z, Chen DC, et al. (2020) Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with Schizophrenia. Schizophr Bull 46: 1498-1510. https://doi.org/10.1093/schbul/sbaa062
    [4] Fervaha G, Foussias G, Agid O, et al. (2014) Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand 130: 290-299. https://doi.org/10.1111/acps.12289
    [5] Keefe RS, Eesley CE, Poe MP (2005) Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57: 688-691. https://doi.org/10.1016/j.biopsych.2005.01.003
    [6] Daskalakis ZJ, Christensen BK, Fitzgerald PB, et al. (2008) Dysfunctional neural plasticity in patients with schizophrenia. Arch Gen Psychiatry 65: 378-385. https://doi.org/10.1001/archpsyc.65.4.378
    [7] Stephan KE, Friston KJ, Frith CD (2009) Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 35: 509-527. https://doi.org/10.1093/schbul/sbn176 6
    [8] Schmitt A, Hasan A, Gruber O, et al. (2011) Schizophrenia as a disorder of discon-nectivity. Eur Arch Psychiatry Clin Neurosci 261: 150-154. https://doi.org/10.1007/s00406-011-0242-2 7
    [9] Hasan A, Falkai P, Wobrock T (2013) Transcranial brain stimulation in schizophre-nia: targeting cortical excitability, connectivity and plasticity. Curr Med Chem 20: 405-413. https://doi.org/10.2174/092986713804870738
    [10] Bhandari A, Voineskos D, Daskalakis ZJ, et al. (2016) A review of impaired neuroplasticity in schizophrenia investigated with non-invasive brain stimulation. Front Psychiatry 7: 45. https://doi.org/10.3389/fpsyt.2016.00045
    [11] Fiş NP, Berkem M (2009) Development of neurotransmitter systems and their reflections on psychopathology. Klin Psikofarmakoloji Bul 19: 311-320.
    [12] Aoyama Y, Mouri A, Toriumi K, et al. (2014) Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int J Neuropsychopharmacol 17: 723-737. https://doi.org/10.1017/S1461145713001466
    [13] Turkmen BA, Yazici E, Erdogan DG, et al. (2021) BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia. BMC Psychiatry 21: 562. https://doi.org/10.1186/s12888-021-03578-4
    [14] Wu Y, Duan Z (2015) Visualization analysis of author collaborations in schizophrenia research. BMC Psychiatry 15: 27. https://doi.org/10.1186/s12888-015-0407-z
    [15] Kiraz S, Demir E (2021) Global scientific outputs of schizophrenia publications from 1975 to 2020: a bibliometric analysis. Psychiatr Q 92: 1725-1744. https://doi.org/10.1007/s11126-021-09937-4
    [16] Colucci-D'Amato L, Speranza L, Volpicelli F (2020) Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci 21: 7777. https://doi.org/10.3390/ijms21207777
    [17] Angelucci F, Brenè S, Mathé A (2005) BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10: 345-352. https://doi.org/10.1038/sj.mp.4001637
    [18] Nieto R, Kukuljan M, Silva H (2013) BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry 4: 45. https://doi.org/10.3389/fpsyt.2013.00045
    [19] Gliwińska A, Czubilińska-Łada J, Więckiewicz G, et al. (2023) The role of brain-derived neurotrophic factor (BDNF) in diagnosis and treatment of epilepsy, depression, schizophrenia, anorexia nervosa and Alzheimer's disease as highly drug-resistant diseases: a narrative review. Brain Sci 13: 163. https://doi.org/10.3390/brainsci13020163
    [20] Hong CJ, Yu YW, Lin CH, et al. (2003) An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 349: 206-208. https://doi.org/10.1016/S0304-3940(03)00828-0
    [21] Penadés R, López-Vílchez I, Catalán R, et al. (2017) BDNF as a marker of response to cognitive remediation in patients with schizophrenia: a randomized and controlled trial. Schizophr Res 197: 458-464. https://doi.org/10.1016/j.schres.2017.12.002
    [22] Nieto RR, Carrasco A, Corral S, et al. (2021) BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review. Front Psychiatry 12: 662407. https://doi.org/10.3389/fpsyt.2021.662407
    [23] Peng S, Li W, Lv L, et al. (2018) BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med 26: 127-136.
    [24] Zhu J, Liu W (2020) A tale of two databases: The use of Web of Science and Scopus in academic papers. Scientometrics 123: 321-335. https://doi.org/10.1007/s11192-020-03387-8
    [25] Pranckutė R (2021) Web of Science (WoS) and Scopus: The titans of bibliographic information in today's academic world. Publications 9: 12. https://doi.org/10.3390/publications9010012
    [26] Page MJ, McKenzie JE, Bossuyt PM, et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: n71. https://doi.org/10.1136/bmj.n71
    [27] Harzing A-W (2010) The Publish or Perish Book: Your guide to Effective and Responsible Citation Analysis. Melbourne, Australia: Tarma Software Research Pty Ltd.
    [28] van Eck NJ, Waltman L (2021) VOSviewer Manual: Manual for VOSviewer version 1.6.17. Leiden: Centre for Science and Technology Studies (CWTS) of Leiden University. Available from: https://www.vosviewer.com/documentation/Manual_VOSviewer_1.6.17.pdf
    [29] Weickert CS, Hyde TM, Lipska BK, et al. (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8: 592-610. https://doi.org/10.1038/sj.mp.4001308
    [30] Gratacòs M, González JR, Mercader JM, et al. (2007) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61: 911-922. https://doi.org/10.1016/j.biopsych.2006.08.025
    [31] Green MJ, Matheson SL, Shepherd A, et al. (2011) Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 16: 960-972. https://doi.org/10.1038/mp.2010.88
    [32] Hashimoto T, Bergen SE, Nguyen QL, et al. (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25: 372-383. https://doi.org/10.1523/JNEUROSCI.4035-04.2005
    [33] Thompson Ray M, Weickert CS, Wyatt E, et al. (2011) Decreased BDNF, TrkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 36: 195-203. https://doi.org/10.1503/jpn.100048
    [34] Neves-Pereira M, Cheung JK, Pasdar A, et al. (2005) BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10: 208-212. https://doi.org/10.1038/sj.mp.4001575
    [35] Ho BC, Milev P, O'Leary DS, et al. (2006) Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 63: 731-740. https://doi.org/10.1001/archpsyc.63.7.731
    [36] Vinogradov S, Fisher M, Holland C, et al. (2009) Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol Psychiatry 66: 549-553. https://doi.org/10.1016/j.biopsych.2009.02.017
    [37] Krebs M, Guillin O, Bourdel MC, et al. (2000) Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5: 558-562. https://doi.org/10.1038/sj.mp.4000749
    [38] Egan MF, Kojima M, Callicott JH, et al. (2003) The BDNF Val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269. https://doi.org/10.1016/s0092-8674(03)00035-7
    [39] Takahashi M, Shirakawa O, Toyooka K, et al. (2000) Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5: 293-300. https://doi.org/10.1038/sj.mp.4000718
    [40] Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276. https://doi.org/10.1093/schbul/13.2.261
    [41] Durany N, Michel T, Zochling R, et al. (2001) Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52: 79-86. https://doi.org/10.1016/s0920-9964(00)00084-0
    [42] Tan YL, Zhou DF, Cao LY, et al. (2005) Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382: 27-32. https://doi.org/10.1016/j.neulet.2005.02.054
    [43] Pan W, Banks WA, Fasold MB, et al. (1998) Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553-1561. https://doi.org/10.1016/s0028-3908(98)00141-5
    [44] Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328: 261-264. https://doi.org/10.1016/s0304-3940(02)00529-3
    [45] Grillo RW, Ottoni GL, Leke R, et al. (2007) Reduced Serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41: 31-35. https://doi.org/10.1016/j.jpsychires.2006.01.005
    [46] Pirildar S, Gönül AS, Taneli F, et al. (2004) Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychopharmacol. Biol Psychiatry 28: 709-713. https://doi.org/10.1016/j.pnpbp.2004.05.008
    [47] Buckley PF, Pillai A, Evans D, et al. (2007) Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 91: 1-5. https://doi.org/10.1016/j.schres.2006.12.026
    [48] Gama CS, Andreazza AC, Kunz M, et al. (2007) Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 420: 45-48. https://doi.org/10.1016/j.neulet.2007.04.001
    [49] Jindal RD, Pillai AK, Mahadik SP, et al. (2010) Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. Schizophr Res 119: 47-51. https://doi.org/10.1016/j.schres.2009.12.035
    [50] Buckley PF, Pillai A, Howell KR (2011) Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatr 24: 122-127. https://doi.org/10.1097/YCO.0b013e3283436eb7
    [51] Thoenen H (1995) Neurotrophins and neuronal plasticity. Science (New York, N.Y.) 270: 593-598. https://doi.org/10.1126/science.270.5236.593
    [52] Altar CA, Cai N, Bliven T, et al. (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389: 856-860. https://doi.org/10.1038/39885
    [53] Guillin O, Diaz J, Carroll P, et al. (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411: 86-89. https://doi.org/10.1038/35075076
    [54] Lipska BK, Khaing ZZ, Weickert CS, et al. (2001) BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 14: 135-144. https://doi.org/10.1046/j.1460-9568.2001.01633.x
    [55] Tan YL, Zhou DF, Cao LY, et al. (2005) Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophr Res 77: 355-356. https://doi.org/10.1016/j.schres.2005.03.012
    [56] Yang F, Wang K, Du X, et al. (2019) Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia. Psychopharmacology 236: 753-762. https://doi.org/10.1007/s00213-018-5107-1
    [57] Wynn JK, Green MF, Hellemann G, et al. (2018) The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophr Res 195: 572-573. https://doi.org/10.1016/j.schres.2017.09.046
    [58] Pawełczyk T, Grancow-Grabka M, Trafalska E, et al. (2019) An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial. Psychopharmacology 236: 2811-2822. https://doi.org/10.1007/s00213-019-05258-4
    [59] Penadés R, López-Vílchez I, Catalán R, et al. (2018) BDNF as a marker of response to cognitive remediation in patients with schizophrenia: A randomized and controlled trial. Schizophr Res 197: 458-464. https://doi.org/10.1016/j.schres.2017.12.002
    [60] Gökçe E, Güneş E, Nalçaci E (2019) Effect of Exercise on Major Depressive Disorder and Schizophrenia: A BDNF Focused Approach. Noropsikiyatri Ars 56: 302-310. https://doi.org/10.29399/npa.23369
    [61] Binford SS, Hubbard EM, Flowers E, et al. (2018) Serum BDNF is positively associated with negative symptoms in older adults with schizophrenia. Biol Res Nurs 20: 63-69. https://doi.org/10.1177/1099800417735634
    [62] Skibinska M, Groszewska A, Kapelski P, et al. (2018) Val66Met functional polymorphism and serum protein level of brain-derived neurotrophic factor (BDNF) in acute episode of schizophrenia and depression. Pharmacol Rep 70: 55-59. https://doi.org/10.1016/j.pharep.2017.08.002
    [63] Atake K, Nakamura T, Ueda N, et al. (2018) The impact of aging, psychotic symptoms, medication, and brain-derived neurotrophic factor on cognitive impairment in Japanese chronic schizophrenia patients. Front Psychiatry 9: 232. https://doi.org/10.3389/fpsyt.2018.00232
    [64] Faatehi M, Basiri M, Nezhadi A, et al. (2019) Early enriched environment prevents cognitive impairment in an animal model of schizophrenia induced by MK-801: Role of hippocampal BDNF. Brain Res 1711: 115-119. https://doi.org/10.1016/j.brainres.2019.01.023
    [65] Guo C, Liu Y, Fang MS, et al. (2020) ω-3PUFAs Improve cognitive impairments through Ser133 phosphorylation of CREB upregulating BDNF/TrkB signal in schizophrenia. Neurotherapeutics 17: 1271-1286. https://doi.org/10.1007/s13311-020-00859-w
    [66] Weickert CS, Lee CH, Lenroot RK, et al. (2019) Increased plasma Brain-Derived Neurotrophic Factor (BDNF) levels in females with schizophrenia. Schizophr Res 209: 212-217. https://doi.org/10.1016/j.schres.2019.04.015
    [67] Mohammadi A, Amooeian VG, Rashidi E (2018) Dysfunction in brain-derived neurotrophic factor signaling pathway and susceptibility to schizophrenia, Parkinson's and Alzheimer's diseases. Curr Gene Ther 18: 45-63. https://doi.org/10.2174/1566523218666180302163029
    [68] Zhang Y, Fang X, Fan W, et al. (2018) Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. Psychopharmacology 235: 1191-1198. https://doi.org/10.1007/s00213-018-4835-6
    [69] Fang X, Chen Y, Wang Y, et al. (2019) Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry 95: 109673. https://doi.org/10.1016/j.pnpbp.2019.109673
    [70] Zhang Y, Fang X, Fan W, et al. (2018) Interaction between BDNF and TNF-α genes in schizophrenia. Psychoneuroendocrinology 89: 1-6. https://doi.org/10.1016/j.psyneuen.2017.12.024
    [71] Han M, Deng C (2020) BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neurosci Lett 726: 133870. https://doi.org/10.1016/j.neulet.2018.10.015
    [72] Xia H, Zhang G, Du X, et al. (2018) Suicide attempt, clinical correlates, and BDNF Val66Met polymorphism in chronic patients with schizophrenia. Neuropsychology 32: 199-205. https://doi.org/10.1037/neu0000383
    [73] Schweiger JI, Bilek E, Schäfer A, et al. (2019) Effects of BDNF Val66Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans. Neuropsychopharmacology 44: 590-597. https://doi.org/10.1038/s41386-018-0248-9
    [74] Huang E, Hettige NC, Zai G, et al. (2019) BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. Pharmacogenomic 19: 269-276. https://doi.org/10.1038/s41397-018-0041-5
    [75] Kim EJ, Kim YK (2018) 196G/A of the Brain-derived neurotrophic factor gene polymorphisms predicts suicidal behavior in schizophrenia patients. Psychiatry Investing 15: 733-738. https://doi.org/10.30773/pi.2018.02.27
    [76] Shoshina II, Hovis JK, Felisberti FM, et al. (2021) Visual processing and BDNF levels in first-episode schizophrenia. Psychiatry Res 305: 114200. https://doi.org/10.1016/j.psychres.2021.114200
    [77] Man L, Lv X, Du XD, et al. (2018) Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Res 263: 1-6. https://doi.org/10.1016/j.psychres.2018.02.034
    [78] Yang Y, Liu Y, Wang G, et al. (2019) Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia. Psychiatry Res 273: 528-536. https://doi.org/10.1016/j.psychres.2019.01.051
    [79] Heitz U, Papmeyer M, Studerus E, et al. (2019) Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World J Biol Psychiatry 20: 545-554. https://doi.org/10.1080/15622975.2018.1462532
    [80] Pillai A, Schooler NR, Peter D, et al. (2018) Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. Schizophr Res 193: 263-268. https://doi.org/10.1016/j.schres.2017.06.059
    [81] Wu RQ, Lin CG, Zhang W, et al. (2018) Effects of risperidone and paliperidone on brain-derived neurotrophic factor and N400 in first-episode schizophrenia. Chin Med J 131: 2297-2301. https://doi.org/10.4103/0366-6999.241802
    [82] Tang X, Zhou C, Gao J, et al. (2019) Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction. BMC Psychiatry 19: 254. https://doi.org/10.1186/s12888-019-2231-3
    [83] Wei C, Sun Y, Chen N, et al. (2020) Interaction of oxidative stress and BDNF on executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology 111: 104473. https://doi.org/10.1016/j.psyneuen.2019.104473
    [84] Ben-Azu B, Aderibigbe AO, Ajayi AM, et al. (2018) Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice. Brain Res Bull 139: 292-306. https://doi.org/10.1016/j.brainresbull.2018.03.006
    [85] Xiu MH, Wang DM, Du XD, et al. (2019) Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology 108: 110-117. https://doi.org/10.1016/j.psyneuen.2019.06.006
    [86] Ahmed HI, Abdel-Sattar SA, Zaky HS (2018) Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway. Naunyn Schmiedeberg's Arch Pharmacol 391: 1327-1338. https://doi.org/10.1007/s00210-018-1552-y
    [87] Wu ZW, Shi H, Chen DC, et al. (2020) BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study. Psychoneuroendocrinology 122: 104879. https://doi.org/10.1016/j.psyneuen.2020.104879
    [88] Xu Y, Deng C, Zheng Y, et al. (2019) Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related PSD-95 in alleviating schizophrenia-like deficits in rat. Compr Psychiatry 94: 152122. https://doi.org/10.1016/j.comppsych.2019.152122
    [89] Di Carlo P, Punzi G, Ursini G (2019) Brain-derived neurotrophic factor and schizophrenia. Psychiatr Genet 29: 200-210. https://doi.org/10.1097/YPG.0000000000000237
    [90] Mizui T, Hattori K, Ishiwata S, et al. (2019) Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia. J Psychiatr Res 113: 190-198. https://doi.org/10.1016/j.jpsychires.2019.03.024
    [91] Hou Y, Liang W, Zhang J, et al. (2018) Schizophrenia-associated rs4702 G allele-specific downregulation of FURIN expression by miR-338-3p reduces BDNF production. Schizophr Res 199: 176-180. https://doi.org/10.1016/j.schres.2018.02.040
    [92] Sasaki T, Dai XY, Kuwata S, et al. (1997) Brain-derived neurotrophic factor gene and schizophrenia in Japanese subjects. Am J Med Genet 74: 443-444.
    [93] Watanabe Y, Muratake T, Kaneko N, et al. (2006) No association between the brain-derived neurotrophic factor gene and schizophrenia in a Japanese population. Schizophr Res 84: 29-35. https://doi.org/10.1016/j.schres.2006.03.011
    [94] Takahashi T, Suzuki M, Tsunoda M, et al. (2008) Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neurosci Lett 435: 34-39. https://doi.org/10.1016/j.neulet.2008.02.004
    [95] Kawashima K, Ikeda M, Kishi T, et al. (2009) BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr Res 112: 72-79. https://doi.org/10.1016/j.schres.2009.03.040
    [96] Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. (2012) Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 27: 33-38. https://doi.org/10.1002/hup.1257
    [97] Krebs MO, Sautel F, Bourdel MC, et al. (1998) Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry 3: 337-341. https://doi.org/10.1038/sj.mp.4000411
    [98] Hawi Z, Straub RE, O'Neill A, et al. (1998) No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families. Psychiatry Res 81: 111-116. https://doi.org/10.1016/s0165-1781(98)00076-6
    [99] de Krom M, Bakker SC, Hendriks J, et al. (2005) Polymorphisms in the brain-derived neurotrophic factor gene are not associated with either anorexia nervosa or schizophrenia in Dutch patients. Psychiatr Genet 15: 81. https://doi.org/10.1097/00041444-200506000-00003
    [100] Chen QY, Chen Q, Feng GY, et al. (2006) Association between the brain-derived neurotrophic factor (BDNF) gene and schizophrenia in the Chinese population. Neurosci Lett 397: 285-290. https://doi.org/10.1016/j.neulet.2005.12.033
    [101] Li W, Zhou N, Yu Q, et al. (2013) Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population. Am J Med Genet B: Neuropsychiatr Genet 162B: 538-545. https://doi.org/10.1002/ajmg.b.32183
    [102] Renjan V, Nurjono M, Lee J (2014) Serum brain-derived neurotrophic factor (BDNF) and its association with remission status in Chinese patients with schizophrenia. Psychiatry Res 220: 193-196. https://doi.org/10.1016/j.psychres.2014.07.079
    [103] Wang Y, Wang JD, Wu HR, et al. (2010) The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population. Schizophr Res 120: 240-242. https://doi.org/10.1016/j.schres.2010.03.020
    [104] Yi Z, Zhang C, Wu Z, et al. (2011) Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res 1417: 146-150. https://doi.org/10.1016/j.brainres.2011.08.037
    [105] Sun MM, Yang LM, Wang Y, et al. (2013) BDNF Val66Met polymorphism and anxiety/depression symptoms in schizophrenia in a Chinese Han population. Psychiatr Genet 23: 124-129. https://doi.org/10.1097/YPG.0b013e328360c866
    [106] Chen SL, Lee SY, Chang YH, et al. (2014) The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 51: 99-104. https://doi.org/10.1016/j.pnpbp.2014.01.012
    [107] Naoe Y, Shinkai T, Hori H, et al. (2007) No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case-control study and meta-analysis. Neurosci Lett 415: 108-112. https://doi.org/10.1016/j.neulet.2007.01.006
    [108] Golimbet VE, Korovaĭtseva GI, Abramova LI, et al. (2008) Association between the Val66Met polymorphism of brain-derived neurotrophic factor gene and schizophrenia in Russians. Mol Biol (Mosk) 42: 599-603. https://doi.org/10.1134/S0026893308040079
    [109] Hashim HM, Fawzy N, Fawzi MM, et al. (2012) Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients. J Psychiatr Res 46: 762-766. https://doi.org/10.1016/j.jpsychires.2012.03.007
    [110] Fawzi MH, Kira IA, Fawzi MM, et al. (2013) Trauma profile in Egyptian adolescents with first-episode schizophrenia: relation to psychopathology and plasma brain-derived neurotrophic factor. J Nerv Ment Dis 201: 23-29. https://doi.org/10.1097/NMD.0b013e31827ab268
    [111] Suchanek R, Owczarek A, Kowalski J (2012) Association study between BDNF C-281A polymorphism and paranoid schizophrenia in Polish population. J Mol Neurosci 46: 217-222. https://doi.org/10.1007/s12031-011-9582-7
    [112] Pełka-Wysiecka J, Wroński M, Jasiewicz A, et al. (2013) BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. Pharmacol Rep 65: 1185-1193. https://doi.org/10.1016/s1734-1140(13)71476-2
    [113] Suchanek R, Owczarek A, Paul-Samojedny M, et al. (2013) BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci 25: 88-94. https://doi.org/10.1176/appi.neuropsych.11100234
    [114] Loh HC, Tang PY, Tee SF, et al. (2012) BDNF and DARPP-32 genes are not risk factors for schizophrenia in the Malay population. Genet Mol Res 11: 725-730. https://doi.org/10.4238/2012.March.22.2
    [115] Kayahan B, Kaymaz BT, Altıntoprak AE, et al. (2013) The lack of association between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms and schizophrenia in a group of Turkish population. Neurol Psychiatry Brain Res 19: 102-108. https://doi.org/10.1016/j.npbr.2013.05.004
    [116] Sözen MA, Sevimli ÖF, Yılmaz M, et al. (2015) Exploratory genetic association study between the BDNF Val66Met polymorphism and schizophrenia in a population from Turkey. Neurol Psychiatry Brain Res 21: 115-117. https://doi.org/10.1016/j.npbr.2015.08.001
    [117] Wang ZR, Zhou DF, Cao LY, et al. (2007) Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia. Schizophr Res 97: 299-301. https://doi.org/10.1016/j.schres.2007.08.012
    [118] Zhang XY, Xiu MH, Chen DC, et al. (2010) Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology 212: 301-307. https://doi.org/10.1007/s00213-010-1956-y
    [119] Zhang XY, Chen DC, Tan YL, et al. (2015) Smoking and BDNF Val66Met polymorphism in male schizophrenia: a case-control study. J Psychiatr Res 60: 49-55. https://doi.org/10.1016/j.jpsychires.2014.09.023
    [120] Zhang XY, Zhou DF, Wu GY, et al. (2008) BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 33: 2200-2205. https://doi.org/10.1038/sj.npp.1301619
    [121] Xiu MH, Hui L, Dang YF, et al. (2009) Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 33: 1508-1512. https://doi.org/10.1016/j.pnpbp.2009.08.011
    [122] Chen DC, Wang J, Wang B, et al. (2009) Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology 207: 375-380. https://doi.org/10.1007/s00213-009-1665-6
    [123] Fiore M, Grace AA, Korf J, et al. (2004) Impaired brain development in the rat following prenatal exposure to methylazoxymethanol acetate at gestational day 17 and neurotrophin distribution. Neuroreport 15: 1791-1795. https://doi.org/10.1097/01.wnr.0000135934.03635.6a
    [124] Ping J, Zhang J, Wan J, et al. (2022) A polymorphism in the BDNF gene (rs11030101) is associated with negative symptoms in Chinese Han patients with schizophrenia. Front Genet 13: 849227. https://doi.org/10.3389/fgene.2022.849227
    [125] van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84: 523-538. https://doi.org/10.1007/S11192-009-0146-3
    [126] van Nunen K, Li J, Reniers G, et al. (2018) Bibliometric analysis of safety culture research. Saf Sci 108: 248-258. https://doi.org/10.1016/j.ssci.2017.08.011
    [127] Li J, Hale A (2015) Identification of, and knowledge communication among core safety science journals. Saf Sci 74: 70-78. https://doi.org/10.1016/j.ssci.2014.12.003
    [128] Zhao D, Strotmann A (2008) Comparing all-author and first-author co-citation analyses of information science. J Informetr 2: 229-239. https://doi.org/10.1016/j.joi.2008.05.004
    [129] Kessler MM (1963) Bibliographic coupling between scientific papers. American Documentation 14: 10-25. https://doi.org/10.1002/asi.5090140103
    [130] van Eck NJ, Waltman L (2014) Visualizing Bibliometric Networks. Measuring Scholarly Impact.Springer Cham.: 285-320. https://doi.org/10.1007/978-3-319-10377-8_13
  • Reader Comments
  • © 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Neuroscience
2.7 4.2

Metrics

Article views(1544) PDF downloads(141) Cited by(0)

Preview PDF
Download XML
Export Citation
Article outline

Figures and Tables

Figures(5)  /  Tables(5)

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog